Remicade

In combination w/ MTX for reduction of signs & symptoms as well as improvement in physical function in patients w/ active disease when response to disease-modifying drugs including MTX has been inadequate; patients w/ severe, active & progressive disease not previously treated w/ MTX or other DMARDs. Moderately to severely active Crohn's disease, fistulising Crohn's disease. Severe active Crohn's disease in ped patients 6-17 yr. Moderately to severely active ulcerative colitis in patients who have had an inadequate response to conventional therapy including corticosteroids & 6-mercaptopurine or azathioprine, or who are intolerant to or have medical contraindications for such therapies. Reducing signs & symptoms & inducing & maintaining clinical remission in ped patients ≥6 yr w/ moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy. Ankylosing spondylitis in patients who have severe axial symptoms, elevated serological markers of inflammatory activity & who have responded inadequately to conventional therapy. In combination w/ MTX for the treatment of active & progressive psoriatic arthritis in patients who have responded inadequately to DMARDs. Moderate to severe plaque psoriasis in adults who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, MTX or PUVA.

IV infusion Adult ≥18 yr RA 3 mg/kg over a 2-hr period, followed by additional 3 mg/kg infusion doses at 2 & 6 wk after the 1st infusion, then every 8 wk thereafter. To be given concomitantly w/ MTX. Moderately to severely, active Crohn's disease, ulcerative colitis, psoriatic arthritis & psoriasis 5 mg/kg over a 2-hr period, followed by additional 5 mg/kg infusion doses at 2 & 6 wk after the initial dose or 1st infusion, then every 8 wk thereafter. Fistulising Crohn's disease Initially 5 mg/kg over a 2-hr period, followed by additional 5 mg/kg infusion doses at 2 & 6 wk after the 1st infusion. In responding patients: Re-administration if disease recurs/additional infusions of 5 mg/kg 8 wkly. Re-administration for Crohn's disease & RA If disease recurs, Remicade can be re-administered w/in 16 wk following the last infusion. Ankylosing spondylitis 5 mg/kg over a 2-hr period, followed by additional 5 mg/kg infusion doses at 2 & 6 wk after the 1st infusion, then every 6-8 wk. Childn 6-17 yr Crohn's disease & ulcerative colitis 5 mg/kg over a 2-hr period, followed by additional 5 mg/kg infusion doses at 2 & 6 wk after the 1st infusion, then every 8 wk thereafter.

Hypersensitivity to infliximab or other murine proteins. TB or other severe infections (eg, sepsis, abscesses, opportunistic infections). Moderate or severe heart failure (NYHA class III/IV).

Disease-Modifying Anti-Rheumatic Drugs (DMARDs) / Immunosuppressants

L04AB02 - infliximab ; Belongs to the class of tumor necrosis factor alpha (TNF-alpha) inhibitors. Used as immunosuppressants.

POM